Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004917 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00004917: Completed Phase 3 study, sponsored by Radiation Therapy Oncology Group.
NCT00004917 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004917, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may stimulate red blood cell production and treat anemia in patients with head and neck cancer. It is not yet known whether receiving radiation therapy with epoetin alfa is more effective than radiation therapy alone in treating anemic patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without epoetin alfa in treating anemic patients who have head and neck cancer.
Interventions
- DRUG cisplatin
- RADIATION radiation therapy
- BIOLOGICAL epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
What the finished NCT00004917 record still lists
NCT00004917 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00004917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004917 about?
NCT00004917 is a clinical study titled "Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may stimulate red blood cell production and treat anemia in patients with head and neck cancer. It is not yet known whether receiving radiation therapy with epoetin alfa is more effective than radiation therapy ...
What is the current status of trial NCT00004917?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-06. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00004917?
The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), epoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004917?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia